Product Overview
MEVAC™ IB VAR 2 is a live-attenuated freeze-dried monovalent vaccine for immunization against Infectious Bronchitis Virus variant-2 (GI-23).
You are viewing Sub-Saharan Africa
MEVAC™ IB VAR 2
MEVAC™ IB VAR 2 is a live-attenuated freeze-dried monovalent vaccine for immunization against Infectious Bronchitis Virus variant-2 (GI-23).
Chickens.
The infectious bronchitis virus (IBV) is the cause of avian infectious bronchitis (IB), which is one of the most highly contagious diseases, resulting in many economic losses in the poultry industry worldwide.1
One emerging genotype of epidemiological importance is the GI-23 lineage (EGY VAR II-like strains) which has shown a widespread prevalence beyond the Middle East, with recent detections reported in Asia, Europe, and Africa. This spread, illustrates the ability of the GI-23 lineage to extend its geographical scope over time and emphasizes the need for comprehensive interventions at farm level.2
It is well established that vaccination must be associated with strict biosecurity measures applied on farms and their surrounding environments to mitigate the viral pressure in the poultry house. Systematic vaccination is the most suitable intervention of combatting IBV. It is accepted that vaccines containing variant 2 antigen should be adopted in those areas affected by this pathogenic strain.2
The use of this vaccine in layer and breeder flocks can help to mitigate respiratory signs and protect against egg production losses during the production phase. Also, the transfer of maternal antibodies to offspring can provide strain-specific immunity for one-day-old chickens.3 One of the most commonly applied vaccination programs against infectious bronchitis (IB) in chickens in affected countries is the protectotype protocol, which consist of simultaneous or alternate use of existing vaccines with classical and variant strains of IB virus for a given IBV field situation. This successful approach decreases the need to develop new homologous vaccines, which is a costly and time-consuming endeavor.3
In chickens from the age of one day: Active immunization to reduce clinical signs associated with Avian Infectious Bronchitis Virus variant-2 (GI-23).
Birds can be vaccinated from first day of age onwards, as per advice from your poultry veterinarian.
Zero days.
The vaccine should be administered via the eye drop, spray, or drinking water routes.
MEVAC™ IB VAR 2 is packed and presented in vials containing a lyophilisate pellet for reconstitution (1000, 2500, 5000 doses).
References
1. Erfanmanesh et al (2020). Evaluation of inactivated vaccine of the variant 2 (IS-1494 /GI-23) genotype of avian infectious bronchitis. Aug; 71: 101497. Published online 2020 May 30. doi: 10.1016/j.cimid.2020.101497
2. Houta et al (2021). The emergence, evolution and spread of infectious bronchitis virus genotype GI‑23. Archives of Virology (2021) 1669–26
3. Smialek et al (2017). Immunological aspects of the efficiency ofprotectotype vaccination strategy against chicken infectious bronchitis. BMC Veterinary Research (2017) 13:44 DOI 10.1186/s12917-017-0963-1.
Fill out the form below to connect with Kemin's vaccine eperts.
The content on this site is intended for informational purposes only and is not intended to be a substitute for professional veterinary advice. Although the information on this site is accessible worldwide, not all products or services are available to all persons or in all geographic locations or jurisdictions. Certain statements, product labeling and claims may differ by geography or as required by local governmental regulations.
© Kemin Industries, Inc. and its group of companies all rights reserved. ® ™ Trademarks of Kemin Industries, Inc., USA
Certain statements may not be applicable in all geographical regions. Product labeling and associated claims may differ based upon government requirements.
You are viewing Sub-Saharan Africa